OptiNose (OPTN) Stock Forecast, Price & News

OptiNose (NASDAQ:OPTN) Frequently Asked Questions

Is OptiNose a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OptiNose stock.
View analyst ratings for OptiNose or view top-rated stocks.

When is OptiNose's next earnings date?

OptiNose is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for OptiNose.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) posted its quarterly earnings data on Thursday, May, 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.04. During the same quarter last year, the business posted ($0.49) earnings per share.
View OptiNose's earnings history.

What guidance has OptiNose issued on next quarter's earnings?

OptiNose issued an update on its FY 2022 earnings guidance on Thursday, May, 19th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $90.00M-, compared to the consensus revenue estimate of $98.82 million.

What price target have analysts set for OPTN?

2 brokerages have issued 12-month price objectives for OptiNose's shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate OptiNose's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 363.9% from the stock's current price.
View analysts' price targets for OptiNose or view top-rated stocks among Wall Street analysts.

Who are OptiNose's key executives?

OptiNose's management team includes the following people:

• Mr. Peter K. Miller, CEO & Director (Age 61, Pay $999.81k) (LinkedIn Profile)
• Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 57, Pay $737.55k) (LinkedIn Profile)
• Mr. Keith Alan Goldan, Chief Financial Officer (Age 51, Pay $600.21k) (LinkedIn Profile)
• Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 46, Pay $604.71k) (LinkedIn Profile)
• Mr. Victor M. Clavelli, Chief Commercial Officer (Age 49, Pay $584.2k) (LinkedIn Profile)
• Mr. Jonathan Neely, VP of Investor Relations & Bus. Operations
• Ms. Karen E. Brophy, Chief HR Officer & VP of HR (Age 59)
• Mr. John Messina, Sr. VP of Clinical Devel. & Medical Affairs
• Ms. Helena Kyttari Djupesland, Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)

Who are some of OptiNose's key competitors?

Some companies that are related to OptiNose include Avidity Biosciences (RNA), Atai Life Sciences (ATAI), PMV Pharmaceuticals (PMVP), SIGA Technologies (SIGA), uniQure (QURE), Atea Pharmaceuticals (AVIR), Design Therapeutics (DSGN), Relmada Therapeutics (RLMD), Zealand Pharma A/S (ZEAL), POINT Biopharma Global (PNT), Eagle Pharmaceuticals (EGRX), Gossamer Bio (GOSS), AnaptysBio (ANAB), Kiniksa Pharmaceuticals (KNSA) and Amarin (AMRN).
View all of OPTN's competitors.

What other stocks do shareholders of OptiNose own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX).

When did OptiNose IPO?

(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

Who are OptiNose's major shareholders?

OptiNose's stock is owned by a number of institutional and retail investors. Top institutional investors include Bleichroeder LP (4.53%), Velan Capital Investment Management LP (2.42%), Vanguard Group Inc. (2.29%), Massachusetts Financial Services Co. MA (2.16%), Rice Hall James & Associates LLC (1.07%) and BlackRock Inc. (0.93%). Company insiders that own OptiNose stock include Joseph C Scodari, Keith A Goldan, Keith A Goldan, Michael F Marino III, Michael F Marino III, Peter K Miller, Peter K Miller, Ramy A Mahmoud, Ramy A Mahmoud and Victor M Clavelli.
View institutional ownership trends for OptiNose.

Which institutional investors are selling OptiNose stock?

OPTN stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., and Simplex Trading LLC. Company insiders that have sold OptiNose company stock in the last year include Keith A Goldan, Michael F Marino III, Peter K Miller, Ramy A Mahmoud, and Victor M Clavelli.
View insider buying and selling activity for OptiNose or view top insider-selling stocks.

Which institutional investors are buying OptiNose stock?

OPTN stock was purchased by a variety of institutional investors in the last quarter, including Velan Capital Investment Management LP, Assenagon Asset Management S.A., State Street Corp, Prelude Capital Management LLC, Jane Street Group LLC, Massachusetts Financial Services Co. MA, Northern Trust Corp, and Easterly Investment Partners LLC. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Keith A Goldan, Michael F Marino III, Peter K Miller, and Victor M Clavelli.
View insider buying and selling activity for OptiNose or or view top insider-buying stocks.

How do I buy shares of OptiNose?

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $1.94.

How much money does OptiNose make?

OptiNose has a market capitalization of $160.40 million and generates $74.65 million in revenue each year. The company earns $-82.30 million in net income (profit) each year or ($1.30) on an earnings per share basis.

How many employees does OptiNose have?

OptiNose employs 189 workers across the globe.

What is OptiNose's official website?

The official website for OptiNose is www.optinose.com.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at (267) 364-3500 or via email at [email protected].